Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06295770 · ClinicalTrials.gov registry record · Phase 2
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
A Phase 2 study of Fibrillary Glomerulonephritis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06295770 is a Phase 2 study of Fibrillary Glomerulonephritis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06295770, a Phase 2 study of Fibrillary Glomerulonephritis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
Conditions Studied
Interventions
- DRUG Obinutuzumab
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06295770
The ClinicalTrials.gov registry entry for NCT06295770 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibrillary Glomerulonephritis appearing as the primary indexed condition, and to 1 intervention - of which Obinutuzumab is the first listed.
NCT06295770 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06295770 about?
NCT06295770 is a clinical study titled "Obinutuzumab in Treatment of Fibrillary Glomerulonephritis". The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
What is the current status of trial NCT06295770?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-06-24. Estimated completion is 2026-05.
What conditions does trial NCT06295770 study?
This clinical trial studies the following conditions: Fibrillary Glomerulonephritis.
What interventions are being tested in trial NCT06295770?
The interventions under investigation include: Obinutuzumab (DRUG).
Who is sponsoring clinical trial NCT06295770?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06295770 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.